GlobeNewsWire
30 Jun 2026, 02:30 UTC · 20w ago
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Impact · against what's priced in
Nuvectis Pharma's $100 million public offering provides necessary capital to fund its NXP100, NXP200, and NXP900 programs, reducing immediate liquidity risk. However, the issuance of 5 million shares at $20.00 creates immediate equity dilution for existing shareholders.
- NVCT−0.10
No priced-in read yet





